2023
Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review
Chuy K, Velazquez E, Lansky A, Jamil Y, Ahmad Y. Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101197. PMID: 39131064, PMCID: PMC11307589, DOI: 10.1016/j.jscai.2023.101197.Peer-Reviewed Original ResearchIschemic systolic heart failureSystolic heart failurePercutaneous coronary interventionHeart failureMedical therapyCoronary revascularizationBenefits of PCITrials of PCILeft ventricular systolic dysfunctionPrevalence of HFBenefit of CABGContemporary medical therapyIschemic ventricular dysfunctionCoronary artery bypassVentricular systolic dysfunctionCoronary artery diseaseIschemic heart diseaseAcute cardiac careComparative clinical effectivenessUnmet clinical needRecent revascularizationArtery bypassSystolic dysfunctionVentricular dysfunctionCoronary intervention
2022
PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes
Ahmad Y, Petrie M, Jolicoeur E, Madhavan M, Velazquez E, Moses J, Lansky A, Stone G. PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100020. PMID: 39132568, PMCID: PMC11307477, DOI: 10.1016/j.jscai.2022.100020.Peer-Reviewed Original ResearchPercutaneous coronary interventionLeft ventricular systolic dysfunctionCoronary artery diseaseHeart failureComplete revascularizationMedical therapyClinical outcomesClinical trialsCoronary artery bypassVentricular systolic dysfunctionClinical trial evidenceHigh operative riskHigh-risk patientsMajor cardiac surgeryExtent of revascularizationMinority of patientsFuture clinical trialsArtery bypassCause mortalityPeriprocedural complicationsSystolic dysfunctionCoronary interventionOperative riskArtery diseaseCardiac surgery
2019
Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction
DeVore AD, Yow E, Krucoff MW, Sherwood MW, Shaw LK, Chiswell K, O'Connor CM, Ohman EM, Velazquez EJ. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. ESC Heart Failure 2019, 6: 1233-1242. PMID: 31560171, PMCID: PMC6989282, DOI: 10.1002/ehf2.12510.Peer-Reviewed Original ResearchConceptsStable coronary artery diseasePercutaneous coronary interventionCoronary artery diseaseVentricular systolic dysfunctionSevere left ventricular systolic dysfunctionLeft ventricular systolic dysfunctionSystolic dysfunctionMedical therapyCardiovascular hospitalizationAddition of PCICanadian Cardiovascular Society class IIIImpact of PCIPercutaneous coronary intervention outcomesDuke University Medical CenterComposite of mortalityPropensity-matched cohortStable coronary diseaseAcute coronary syndromeHigh-risk patientsLong-term mortalityVentricular ejection fractionCox proportional hazardsUniversity Medical CenterCause mortalityCoronary syndromeDoes prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial
Nicolau JC, Stevens SR, Al-Khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-Nickens P, Haddad H, Jolicoeur EM, Petrie MC, Doenst T, Michler RE, Ohman EM, Maddury J, Ali I, Deja MA, Rouleau JL, Velazquez EJ, Hill JA. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International Journal Of Cardiology 2019, 291: 36-41. PMID: 30929973, PMCID: PMC6579621, DOI: 10.1016/j.ijcard.2019.03.029.Peer-Reviewed Original ResearchConceptsPrior percutaneous coronary interventionPercutaneous coronary interventionLeft ventricular ejection fractionSTICH trialCV hospitalizationCV mortalityCause mortalityMedical treatmentSuperiority of CABGOutcomes of patientsSurgical coronary revascularizationCoronary artery bypassVentricular ejection fractionArtery bypassCoronary revascularizationCoronary interventionCoronary angioplastyEjection fractionMedian timeWorse prognosisRandomized treatmentCABGHospitalizationMortalityPatientsPCI and CABG for Treating Stable Coronary Artery Disease JACC Review Topic of the Week
Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, Velazquez E, Diegeler A, Sigusch H. PCI and CABG for Treating Stable Coronary Artery Disease JACC Review Topic of the Week. Journal Of The American College Of Cardiology 2019, 73: 964-976. PMID: 30819365, DOI: 10.1016/j.jacc.2018.11.053.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionMyocardial infarctionStable coronary artery diseaseMajority of infarctsCoronary artery bypassCoronary artery diseaseFlow-limiting lesionsNew infarctsArtery bypassCoronary interventionInfarct reductionArtery diseaseMedical therapyRevascularization proceduresVessel occlusionCABGSurvival effectReview TopicTreatment effectsInfarctionInfarctsIschemia detectionRevascularizationStenosisBypass
2017
Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease
Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease. Journal Of The American Heart Association 2017, 6: e006044. PMID: 29021274, PMCID: PMC5721834, DOI: 10.1161/jaha.117.006044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAortic ValveAortic Valve StenosisComorbidityDatabases, FactualEchocardiographyFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidneyMaleMiddle AgedMitral ValveMitral Valve InsufficiencyNorth CarolinaPrevalencePrognosisProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesRisk FactorsSeverity of Illness IndexSex FactorsTime FactorsConceptsChronic kidney diseaseFive-year survival estimatesNon-CKD patientsCKD patientsMitral regurgitationMR severityKidney diseaseSurvival estimatesCoronary artery bypassGlomerular filtration ratePercutaneous coronary interventionSevere mitral regurgitationValvular heart diseaseSerum creatinine valuesAdverse prognostic markerRegurgitant valve lesionsIndex echocardiogramSevere ASArtery bypassIntervention patientsValve lesionsValve surgeryCoronary interventionHazard ratioHeart failure
2014
Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation
Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, Lopes RD, Alexander JH, Mathew JP, Velazquez EJ, Milano CA, Smith PK. Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation. Circulation 2014, 129: 2547-2556. PMID: 24744275, PMCID: PMC4142433, DOI: 10.1161/circulationaha.113.005223.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassDatabases, BibliographicFemaleFollow-Up StudiesHeart Valve Prosthesis ImplantationHumansKaplan-Meier EstimateMaleMiddle AgedMitral ValveMitral Valve InsufficiencyMyocardial IschemiaMyocardial RevascularizationPercutaneous Coronary InterventionProportional Hazards ModelsRetrospective StudiesRisk FactorsSeverity of Illness IndexStentsConceptsIschemic mitral regurgitationPercutaneous coronary interventionMitral valve repairSignificant coronary artery diseaseSevere ischemic mitral regurgitationCoronary artery diseaseMitral regurgitationCoronary interventionValve repairMedical treatmentArtery diseaseTreatment strategiesLower mortalityMultivariable Cox proportional hazards analysisCox proportional hazards analysisCoronary artery bypassMitral valve surgeryKaplan-Meier methodProportional hazards analysisMitral regurgitation severitySurgical revascularizationArtery bypassValve surgeryOptimal treatmentCABG
2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 2009, 30: 1450-1456. PMID: 19346225, DOI: 10.1093/eurheartj/ehp102.Peer-Reviewed Original ResearchConceptsPrior CABG patientsCoronary artery bypassMyocardial infarctionCABG patientsPrior CABGHeart failureArtery bypassNon-Q-wave myocardial infarctionPrior coronary artery bypassAcute Myocardial Infarction trialPrimary percutaneous coronary interventionKaplan-Meier ratesSecondary preventive therapyWorse clinical profileMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsPercutaneous coronary interventionAcute myocardial infarctionNumber of patientsNon-fatal outcomesHospital presentationLess aspirinMore comorbiditiesCardiovascular death
2008
Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention
Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention. The American Journal Of Cardiology 2008, 103: 355-360. PMID: 19166689, DOI: 10.1016/j.amjcard.2008.09.088.Peer-Reviewed Original ResearchConceptsElective percutaneous coronary interventionPercutaneous coronary interventionHospital mortalityEjection fractionCoronary interventionOdds ratioLeft ventricular systolic dysfunctionHospital mortality increasesReduced ejection fractionRetrospective cohort studyVentricular systolic dysfunctionLeft ventricular dysfunctionLow ejection fractionLV ejection fractionAdjusted hospital mortalitySystolic dysfunctionVentricular dysfunctionCohort studyMultivariate adjustmentMedical therapyEF groupPatientsMortalityOutcome variablesMortality increases
2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, Investigators F. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Pressure 2007, 16: 13-19. PMID: 17453747, DOI: 10.1080/08037050701217643.Peer-Reviewed Original ResearchConceptsBody mass indexHigh cardiovascular riskCardiovascular eventsHypertensive patientsCardiovascular riskDiabetes mellitusCombination therapyNon-fatal cardiovascular endpointsCoronary artery bypass graftMean body mass indexAnti-lipid therapyAvoiding Cardiovascular EventsOral diabetes therapyPrevious antihypertensive treatmentSystolic Hypertension (ACCOMPLISH) trialDouble-blind treatmentAcute coronary syndromeArtery bypass graftAntihypertensive combination therapyHistory of strokePercutaneous coronary interventionAnti-platelet agentsACCOMPLISH trialAntihypertensive treatmentCardiovascular morbidity
2006
Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose.
Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose. The American Journal Of Cardiology 2006, 99: 315-321. PMID: 17261389, DOI: 10.1016/j.amjcard.2006.08.031.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAfrican American patientsMyocardial infarctionWhite patientsCoronary syndromeSegment elevation (NSTE) ACSST-segment elevation acute coronary syndromeElevation acute coronary syndromeBaseline clinical characteristicsFrequency of hypertensionNonfatal myocardial infarctionThirty-day deathCoronary artery bypassHigh-risk patientsOutcomes of patientsSanofi-AventisPercutaneous coronary interventionUse of angiographyNorth American patientsRacial differencesAfrican AmericansSYNERGY trialArtery bypassClinical characteristicsCoronary intervention